8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                    FORM 8-K


                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the

                         Securities Exchange Act of 1934

          Date of Report (Date of earliest event reported) June 8, 2004


                         COMPETITIVE TECHNOLOGIES, INC.
             (Exact name of registrant as specified in its charter)


Delaware                      1-8696                     36-2664428
- ------------------            ----------------           ----------------
(State or other               (Commission File           (IRS Employer
jurisdiction                  Number)                     Identification No.)
of incorporation)




1960 Bronson Road, Fairfield, Connecticut            06824
- ----------------------------------------------------------------------
(Address of principal executive offices)         (Zip Code)


Registrant's telephone number, including area code  (203) 255-6044
                                                   ----------------

                                 Not Applicable
- --------------------------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)





Item 5.  Other Events and Regulation FD Disclosure.

     On June 8, 2004, the U.S. Court of Appeals for the Federal Circuit affirmed
the November 2002 decision in favor of the Company and Metabolite  Laboratories,
Inc. in the LabCorp litigation.

     LabCorp now has limited  legal  options  available to them,  and may either
request a rehearing  en banc or file a petition  to appeal this  decision to the
U.S.  Supreme Court,  or both. We do not know what course of action LabCorp will
take; however, ultimately we expect that the decision of the court will continue
to be upheld in our favor.

     We have not received  any cash nor have we recorded any revenue  related to
the damages  awarded in this  decision.  We will  record any  revenue  from this
decision when this decision is final and unappealable.

     For further information relating to this lawsuit, please refer to the
discussion under the caption "LabCorp" under "Legal Proceedings" in the
Prospectus filed with the Securities and Exchange Commission on May 6, 2004,
under Rule 424(b)(3) of the Securities Act of 1933.


Item 7.  Financial Statements and Exhibits.

(c)      Exhibits.

         Exhibit No.       Description of Exhibit                           Page
         -----------       ----------------------

         99.1              Registrant's press release dated
                           June 8, 2004                                      3-4



                                    Signature
                                    ---------


     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                          COMPETITIVE TECHNOLOGIES, INC.
                                          Registrant


Date:  June 9, 2004                       /s/  John B. Nano
                                          -------------------------
                                          By:  John B. Nano
                                          President and
                                          Chief Executive Officer

EX-99.1

                                                                    Exhibit 99.1


           COMPETITIVE TECHNOLOGIES WINS IN HOMOCYSTEINE CASE AGAINST
                        LABCORP AT FEDERAL CIRCUIT COURT


Fairfield, CT (June 8, 2004) Competitive Technologies, Inc. (AMEX: CTT)
announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) has
affirmed the November 2002 decision of Senior Judge Zita L. Weinshienk of the
Colorado U.S. District Court (CDC). The CAFC decision reaffirmed that Laboratory
Corporation of America Holdings (LabCorp) willfully contributed to and induced
infringement of CTT's homocysteine assay patent. The CAFC ruling positively
upholds the validity of CTT's patent rights and the November 2001 jury decision
that found in favor of CTT, its clients the University of Colorado and Columbia
University, and its licensee Metabolite Laboratories, Inc. (MLI).

CTT expects to receive approximately $1.2 million of the $2.1 million the CDC
awarded to CTT, the University of Colorado and Columbia University, and $4.5
million to MLI in damages and interest in this five-year old case. LabCorp
posted a $6.6 million bond to stay execution of the monetary judgement granted
in favor of CTT by the CDC and to stay a permanent injunction from performing
homocysteine assays. In December 2002, CTT and LabCorp reached an agreement
under which LabCorp immediately began paying CTT a 6% royalty on all
homocysteine assays conducted by LabCorp under CTT's patent rights. The assay
patent is derived from discoveries made by CTT's clients, Drs. Robert Allen and
Sally Stabler from the University of Colorado and the late Dr. John Lindenbaum
from Columbia University.

John B. Nano, CTT's President and CEO said, "We are pleased that the CAFC has
found in favor of CTT and our clients in this important homocysteine assay
patent infringement case. We will intensify our program for the collection of
all previously withheld royalties from other labs for current and retroactive
fees. We believe there are now over 20 million assays conducted annually, with
this number is growing substantially each year. CTT expects to earn several
millions of dollars of revenue as a result of this court decision. The
homocysteine assay benefits society in keeping with our strategy of finding
technology solutions that satisfy customer needs and add to shareholder value."

"Elevated levels of homocysteine resulting from vitamin B12 and folate
deficiency have been associated with cardiovascular and vascular disease,
Alzheimer's, rheumatoid arthritis and other diseases," continued Mr. Nano.
"These elevated levels are found in one cardiovascular patient of every three,
or approximately 20 million Americans. The homocysteine assay is an important
element of routine diagnosis, annual monitoring and effective treatment."

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is a full service technology
transfer and licensing provider focused on the technology needs of its customers
and transforming those requirements into commercially viable solutions. CTT is a
global leader in identifying, developing and commercializing innovative
technologies in life, digital, nano, and physical sciences developed by
universities, companies and inventors. The global market for technology transfer
services is estimated at $150 billion annually. CTT maximizes the value of
intellectual assets for the benefit of its customers, clients and shareholders.
Visit CTT's website: http://www.competitivetech.net

Statements about the Company's future expectations, including development and
regulatory plans, and all other statements in this document other than
historical facts are "forward-looking statements" within the meaning of
applicable Federal Securities Laws and are not guarantees of future performance.
These statements involve risks and uncertainties, including those set forth in
Item 1 of the Company's most recent Form 10-K and in CTT's other filings with
the SEC, and are subject to change at any time. The Company's actual results
could differ materially from these forward-looking statements. The Company
undertakes no obligation to update publicly any forward-looking statement.

Direct inquiries to: Johnnie D. Johnson, Strategic IR, Inc.
                     Tel. (212) 754-6565; Fax (212) 754-4333

                     E-mail: jdjohnson@strategic-ir.com
                     E-mail: ctt@competitivetech.net